Two Sigma Securities LLC Invests $1.68 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Two Sigma Securities LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,585 shares of the biopharmaceutical company’s stock, valued at approximately $1,681,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Geneos Wealth Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 175 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $241,000. Daiwa Securities Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% during the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 703 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Barclays decreased their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Chardan Capital restated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Finally, Stifel Nicolaus reduced their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $237.10 on Monday. The firm has a market cap of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm’s fifty day moving average is $262.62 and its 200 day moving average is $293.54. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.51) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.